Deeper inhibition of the MAPK pathway by targeting both MEK and BRAF may help improve progression-free survival outcomes in patients with advanced BRAF V600–mutated melanoma.
A secondary cytoreductive surgery along with chemotherapy following recurrence in patients with epithelial ovarian cancer offered improved outcomes over treatment with chemotherapy alone.
The presence and burden of single nucleotide variants as measured in cell-free DNA may have substantial prognostic utility in patients with melanoma who have metastases.
Researchers have developed a “disease screening pill” that could allow for a noninvasive and safe method for detecting breast cancer using only near-infrared light.
Trabectedin plus pegylated liposomal doxorubicin offered clinical benefit in a real-life setting of patients with previously treated platinum-sensitive recurrent ovarian cancer.
An intravesical instillation of gemcitabine following TURBT reduced the risk of recurrence in patients with suspected low-grade non–muscle-invasive urothelial cancer.
The US Preventive Services Task Force issued a final recommendation on prostate cancer screening, including that men aged 55 to 69 years should make an individual decision on whether or not to be screened.
A neoadjuvant dose-dense regimen was active and well tolerated in patients with muscle-invasive bladder cancer, allowing downstaging of most patients before radical cystectomy.
New research has found that expression of AXL is correlated with poor outcomes in patients with HER2-positive breast cancer.
An analysis of patient-reported outcomes showed that osimertinib yielded a longer time to deterioration compared with chemotherapy in patients with advanced non–small-cell lung cancer.